Mercury Bio, a New Mexico-based biotech company, has developed a biomolecular, advanced drug delivery system (ADDS) for highly targeted delivery of RNA therapeutics as well as small-molecule drugs, to targeted diseased cells.

The new biomolecular drug delivery platform is said to reduce the roadblocks encountered by RNA therapeutics and small-molecule drugs in vivo.

Mercury Bio said that it designed the platform by using naturally occurring vesicles for encapsulating RNA therapeutics and small-molecule drugs. The vesicles were modified to show a cell-specific targeting process.

The latest platform can simultaneously address the challenges with drug potency and drug targeting specificity, claimed the company.

Mercury Bio CEO Bruce McCormick said: “Curing many diseases now does not require new drugs; it needs new drug delivery systems. The ability to deliver RNA and small-molecule drugs directly to target cells is a reality that will change the way we approach disease.”

The new biomolecular drug delivery platform was a result of research work associated with RNA treatment for Covid-19. The firm found that the off-target drug delivery was a highly important limiting factor, like the case with small-molecule drugs.

The biotech company aimed to develop an efficient enhanced drug delivery system with a wide range of uses beyond battling Covid-19.

The company’s original name was Spartina Biotechnologies, which was changed to Mercury Bio in 2022. It is now expanding its activities in Santa Fe, New Mexico by extending the laboratory space and hiring new scientists to the team.

Mercury Bio is also said to be assembling private equity investments and exploring new research collaborations.